These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16355548)

  • 61. Is anemia of cancer different from chemotherapy-induced anemia?
    Steensma DP
    J Clin Oncol; 2008 Mar; 26(7):1022-4. PubMed ID: 18227523
    [No Abstract]   [Full Text] [Related]  

  • 62. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Epoetin: for better or for worse?
    Lancet Oncol; 2004 Jan; 5(1):1. PubMed ID: 14700601
    [No Abstract]   [Full Text] [Related]  

  • 64. Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
    Kelaidi C; Fenaux P
    Expert Opin Biol Ther; 2010 Apr; 10(4):605-14. PubMed ID: 20201708
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment of anemia with darbepoetin alfa in the radiation oncology setting.
    Finney D; Allison RR
    J Support Oncol; 2005; 3(6 Suppl 4):6-7. PubMed ID: 16355547
    [No Abstract]   [Full Text] [Related]  

  • 67. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.
    Abraham I; Han L; Sun D; MacDonald K; Aapro M
    Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment.
    Ludwig H; Fritz E
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):35-8. PubMed ID: 9671328
    [TBL] [Abstract][Full Text] [Related]  

  • 70. No rest for fatigue researchers.
    McNeil C
    J Natl Cancer Inst; 2008 Aug; 100(16):1129-31. PubMed ID: 18695127
    [No Abstract]   [Full Text] [Related]  

  • 71. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
    Więcek A; Ahmed I; Scigalla P; Koytchev R
    Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Anaemia in cancer patients: pathophysiology, incidence and treatment.
    Bokemeyer C; Oechsle K; Hartmann JT
    Eur J Clin Invest; 2005 Dec; 35 Suppl 3():26-31. PubMed ID: 16281955
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia".
    Coiffier B
    Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359
    [No Abstract]   [Full Text] [Related]  

  • 74. Erythropoietin, the FDA, and oncology.
    Steinbrook R
    N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
    [No Abstract]   [Full Text] [Related]  

  • 75. Therapeutic interchange of darbepoetin alfa for epoetin alfa in a multiinstitution health care system.
    Adamson R; Lew I; Allen P; Misuro A; Malacrida P
    Am J Health Syst Pharm; 2005 Nov; 62(22):2416-9. PubMed ID: 16278336
    [No Abstract]   [Full Text] [Related]  

  • 76. The emerging role of darbepoetin alfa in the management of patients with cancer.
    Gordon MS
    J Support Oncol; 2004; 2(2 Suppl 2):2-3. PubMed ID: 16108417
    [No Abstract]   [Full Text] [Related]  

  • 77. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.
    Bohlius J; Wilson J; Seidenfeld J; Piper M; Schwarzer G; Sandercock J; Trelle S; Weingart O; Bayliss S; Djulbegovic B; Bennett CL; Langensiepen S; Hyde C; Engert A
    J Natl Cancer Inst; 2006 May; 98(10):708-14. PubMed ID: 16705125
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Darbepoetin Alfa Versus Erythropoietin Alfa for Treatment of Renal Anemia in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage: A Randomized Non-inferiority Trial.
    Mehta KS; Sinha SD; Vamsi B; Reddy B; Naidu NR; Thakur PA; Sreenivasa C; Reddy VPR; Pandey R; Durugkar S
    J Assoc Physicians India; 2019 Jan; 67(1):62-66. PubMed ID: 30935177
    [No Abstract]   [Full Text] [Related]  

  • 79. Managing anemia in patients with chronic kidney disease or cancer: development and role of darbepoetin alfa.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):129S-132S. PubMed ID: 12222582
    [No Abstract]   [Full Text] [Related]  

  • 80. Darbepoetin alfa controversies, from dosage issues to safety concerns: the larger lesson.
    Glaspy JA
    Oncology (Williston Park); 2011 Apr; 25(5):423-4. PubMed ID: 21710839
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.